Search for Clinical Trial Results

Sponsored By

Optic Atrophy - 62 Studies Found

Status Study
Recruiting Study Name: Advanced Characterization of Autosomal Dominant Optic Atrophy
Condition: Optic Atrophy, Autosomal Dominant
Date: 2011-11-30
Recruiting Study Name: Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Date: 2010-11-24
Completed Study Name: Transcorneal Electrical Stimulation Therapy for Retinal Disease
Condition:
  • Retinitis Pigmentosa
  • Macula Off
  • Primary Open Angle Glaucom
    Date: 2008-12-05
    Interventions:
    • Device: Transcorneal Electrical Stimulation

Recruiting Study Name: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Condition:
  • Rare Disorders
  • Undiagnosed Disorders
  • Disorders of Unknown
    Date: 2013-02-13
Recruiting Study Name: Stem Cell Ophthalmology Treatment Study II
Condition:
  • Retinal Disease
  • Age-Related Macular Degeneration
  • Retinitis
    Date: 2017-01-01
    Interventions:
    • Procedure: Arm 1

Recruiting Study Name: Advanced Characterization of Autosomal Dominant Optic Atrophy
Condition: Optic Atrophy, Autosomal Dominant
Date: 2011-11-30
Completed Study Name: Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
Condition:
  • Optic Atrophy
  • Non-arteritic Anterior Ischemic Optic Neuropathy<
    Date: 2010-02-04
    Interventions: Drug: QPI-1007 at various doses Single Intravitreal Injection
Completed Study Name: Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease
Condition: Optic Atrophy
Date: 2013-02-26
Interventions: Biological: STEM CELL THERAPY Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of
Completed Study Name: A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)
Condition: Optic Atrophy, Hereditary, Leber
Date: 2007-09-11
Interventions: Drug: curcumin curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the seco
Completed Study Name: Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Date: 2010-11-24
Next >>>